Dierssen M, Màrmol F, Vivas N M, Clos M V, Gascón S, Badia A
Departament de Farmacologia i Psiquiatria, Universitat Autònoma de Barcelona, Bellaterra, Spain.
Neurosci Lett. 1991 Oct 28;132(1):51-4. doi: 10.1016/0304-3940(91)90431-r.
The effects of acute treatment with 1,2,3,4-tetrahydro-9-aminoacridine (THA), a 4-aminopyridine derivative clinically effective in Alzheimer's disease, on beta-adrenoceptor-linked cyclic AMP accumulation have been investigated in cortical and hippocampal structures of young and middle-aged rats. In a first series of experiments, pretreatment with 2.5 mg/kg THA decreased basal cyclic AMP accumulation. When a phosphodiesterase inhibitor was added to the preparation, THA again decreased cyclic AMP levels in young rats, but failed to significantly modify cyclic AMP accumulation in middle-aged animals. Finally, in isoprenaline-stimulated conditions, acute treatment with tacrine was able to diminish cyclic AMP accumulation in every group of rats. It is suggested that the neurochemical action of THA in mammalian brain is more complex than earlier has been anticipated and may involve an action on beta-adrenoceptors.
1,2,3,4-四氢-9-氨基吖啶(THA)是一种临床上对阿尔茨海默病有效的4-氨基吡啶衍生物,研究了其急性处理对年轻和中年大鼠皮质及海马结构中β-肾上腺素能受体相关环磷酸腺苷(cAMP)积累的影响。在第一组实验中,用2.5mg/kg THA预处理可降低基础cAMP积累。当向制剂中加入磷酸二酯酶抑制剂时,THA再次降低了年轻大鼠的cAMP水平,但未能显著改变中年动物的cAMP积累。最后,在异丙肾上腺素刺激的条件下,用他克林急性处理能够减少每组大鼠的cAMP积累。提示THA在哺乳动物脑中的神经化学作用比之前预期的更为复杂,可能涉及对β-肾上腺素能受体的作用。